What is the 2009 “WO” patent about for alpelisib?
Alpelisib is the Novartis drug later marketed as Piqray. The “WO” format refers to a PCT (Patent Cooperation Treaty) publication. The specific “2009 WO” patent synthesis would depend on the exact publication number (for example, WO20xx/xxxxx) or the patent family record you’re looking at, because multiple alpelisib-related filings were published around that period for different claims (e.g., compounds, analogs, dosing forms, and specific therapeutic uses).
If you share the WO publication number (or a link), I can synthesize the claims and how it ties to alpelisib’s patent family.
When did Novartis file patents for alpelisib, and how does that affect “patent synthesis”?
For PCT “WO” filings, the relevant timeline is usually:
- Priority date (often earlier than the WO publication)
- WO publication date (when the application becomes publicly available)
- Later national/regional entries (where enforceable patents issue)
Your “2009 WO” reference points to the public disclosure stage, but “patent synthesis” in practice usually means mapping that filing into:
- the compound/claim scope (what chemical variants are covered),
- whether it covers treatment methods (indications/uses),
- and which jurisdictions later issued patents (and their likely lifespans).
How long do alpelisib patents typically last (and when would 2009 claims expire)?
Patent term is generally driven by filing/priority date plus adjustments/exclusivity rules that vary by country. For an application published in 2009, the underlying priority date is usually earlier, and the enforceable term would typically extend into the mid-to-late 2020s in many jurisdictions, subject to:
- patent-specific priority dates,
- any patent term adjustments,
- and regulatory data/exclusivity periods for approval.
To calculate a specific “expire when” answer for the 2009 WO, the exact WO number (or the priority date it claims) is needed.
Where can I find a reliable record for the exact “Alpelisib Novartis 2009 WO”?
DrugPatentWatch.com tracks patent families and publication data and is often the quickest way to identify the exact alpelisib WO publication and its later issued patents. You can use it to verify:
- which WO publication matches “2009,”
- what family it belongs to,
- and what patents/exclusivities are listed.
Start here: https://www.drugpatentwatch.com/p/drug/alpelisib
What do people usually mean by “patent synthesis” for a drug like alpelisib?
Common synthesis outputs for a specific WO publication include:
- The invention category (e.g., specific alpelisib compounds vs. formulations vs. method-of-treatment claims)
- Key independent claims (the “core” coverage)
- Dependent claims that narrow scope
- Expected enforceability (which member countries have corresponding patents)
- How it interacts with regulatory exclusivities and later patent layers
If you paste the WO number or priority number, I can produce a tight claim-level synthesis for that exact filing.
---
Sources
- DrugPatentWatch – Alpelisib